GlobeNewswire - Industry News on Medical EquipmentContains the last 20 releasesuuid:ce268c8c-6725-45d1-9abb-7dd1cefbc5a0;id=126502020-06-05T20:05:00Znewsdesk@globenewswire.com (NewsDesk)http://www.globenewswire.com/LegacyRss?Length=4newsdesk@globenewswire.comhttp://www.globenewswire.com/news-release/2020/06/05/2044490/0/en/Sarepta-Therapeutics-to-Share-Clinical-Update-from-SRP-9003-Gene-Therapy-Trial-to-Treat-Limb-girdle-Muscular-Dystrophy-Type-2E-or-Beta-Sarcoglycanopathy.htmlSarepta Therapeutics to Share Clinical Update from SRP-9003 Gene Therapy Trial to Treat Limb-girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy 2020-06-05T20:05:00Z2020-06-07T10:12:17ZCAMBRIDGE, Mass., June 05, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, June 8, 2020 at 8:30 am Eastern Time (ET), it will host a webcast and conference call to present new data from the ongoing study of SRP-9003, an investigational gene therapy to treat Limb-girdle muscular dystrophy Type 2E, or beta-sarcoglycanopathy. Results will include expression and safety results from the high dose cohort and one-year functional results from the low dose cohort.]]>2044490enGlobeNewswire Inc.Sarepta Therapeutics, Inc.Fri, 05 Jun 2020 20:05 GMTCalendar of EventsHealthhttp://www.globenewswire.com/news-release/2020/06/05/2044473/0/en/Alychlo-has-successfully-completed-a-private-sale-of-shares-in-Fagron.htmlAlychlo has successfully completed a private sale of shares in Fagron2020-06-05T19:00:30Z2020-06-07T10:12:17ZNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA), AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.]]>2044473enGlobeNewswire Inc.Fagron NVFri, 05 Jun 2020 19:00 GMTOther NewsEuropean Regulatory Newshttp://www.globenewswire.com/news-release/2020/06/05/2044473/0/nl/Alychlo-heeft-een-private-verkoop-van-aandelen-in-Fagron-succesvol-afgerond.htmlAlychlo heeft een private verkoop van aandelen in Fagron succesvol afgerond2020-06-05T19:00:30Z2020-06-07T10:12:17ZDEZE AANKONDIGING IS NIET VOOR VERSPREIDING, RECHTSTREEKS OF ONRECHTSTREEKS, IN DE VERENIGDE STATEN VAN AMERIKA (MET INBEGRIP VAN HAAR GRONDGEBIED EN BEZITTINGEN, ENIGE STAAT VAN DE VERENIGDE STATEN EN HET DISTRICT COLUMBIA), AUSTRALIË, CANADA, JAPAN, ZUID-AFRIKA OF ENIGE ANDERE JURISDICTIE WAAR DAT VERBODEN ZOU ZIJN DOOR TOEPASSELIJKE WETGEVING.]]>2044473nlGlobeNewswire Inc.Fagron NVFri, 05 Jun 2020 19:00 GMTOther NewsEuropean Regulatory Newshttp://www.globenewswire.com/news-release/2020/06/05/2044325/0/en/ViralClear-adds-St-David-s-HealthCare-in-Austin-Texas-to-its-Planned-Phase-II-trial-for-its-Broad-Spectrum-Oral-Anti-Viral-Candidate-for-COVID-19.htmlViralClear adds St. David's HealthCare in Austin, Texas, to its Planned Phase II trial for its Broad-Spectrum Oral Anti-Viral Candidate for COVID-192020-06-05T13:10:00Z2020-06-07T10:12:17ZRandomized, double-blind, placebo-controlled Phase II trial of merimepodib to be conducted in adults with COVID-19 who are hospitalized and require supplemental oxygen or are on non-invasive ventilation or high-flow oxygen devices]]>2044325enGlobeNewswire Inc.BioSig Technologies, Inc.Fri, 05 Jun 2020 13:10 GMTCompany AnnouncementHEALTHMEDICALelectrophysiologystocknasdaqdeviceinvestorarrhythmiaAfibVTheartEPscienceablationbioelectronic medicinehttp://www.globenewswire.com/news-release/2020/06/05/2044317/0/en/Medtronic-Resolute-Onyx-DES-Receives-First-and-Only-One-Month-DAPT-Indication-for-High-Bleeding-Risk-Patients-in-Europe.htmlMedtronic Resolute Onyx™ DES Receives First and Only One-Month DAPT Indication for High Bleeding Risk Patients in Europe2020-06-05T13:00:00Z2020-06-07T10:12:17ZDUBLIN, June 05, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received CE (Conformité Européenne) Mark for a one-month dual antiplatelet therapy (DAPT) indication for high bleeding risk (HBR) patients implanted with the Resolute Onyx™ Drug-Eluting Stent (DES). For HBR patients, whose bleeding risk may be increased by taking longer DAPT regimens (a combination of aspirin and anti-clotting medication), this new, first-of-its-kind indication allows physicians to recommend a shorter, one-month regimen of DAPT, following a percutaneous coronary intervention (PCI) with Resolute Onyx. The approval is the first of its kind globally. Resolute Onyx DES is available for use in the United States, as well as in Europe and other countries that recognize the CE Mark. Resolute Onyx DES is not currently indicated for HBR patients with one-month DAPT in the United States. Data have been submitted to the FDA with the intent of obtaining a one-month DAPT US Indication for Resolute Onyx DES.]]>2044317enGlobeNewswire Inc.Medtronic plcFri, 05 Jun 2020 13:00 GMTCompany AnnouncementProduct / Services Announcementhttp://www.globenewswire.com/news-release/2020/06/05/2044079/0/en/Aurora-Spine-Corporation-Announces-2019-Year-End-Results.htmlAurora Spine Corporation Announces 2019 Year End Results2020-06-05T00:20:59Z2020-06-07T10:12:17ZNOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES]]>2044079enGlobeNewswire Inc.Aurora Spine CorporationFri, 05 Jun 2020 00:20 GMTCompany Announcementhttp://www.globenewswire.com/news-release/2020/06/04/2043769/0/en/BioSig-Technologies-s-PURE-EP-System-to-be-Presented-in-Heart-Rhythm-Society-2020-Science-Sessions.htmlBioSig Technologies’s PURE EP System to be Presented in Heart Rhythm Society 2020 Science Sessions2020-06-04T13:25:00Z2020-06-07T10:12:17ZCompany’s flagship biomedical signal processing platform highlighted in two scientific sessions presented by key opinion leaders from Mayo Clinic ]]>2043769enGlobeNewswire Inc.BioSig Technologies, Inc.Thu, 04 Jun 2020 13:25 GMTCompany AnnouncementHEALTHMEDICALelectrophysiologystocknasdaqdeviceinvestorarrhythmiaAfibVTheartEPscienceablationbioelectronic medicinehttp://www.globenewswire.com/news-release/2020/06/04/2043737/0/en/Neovasc-Announces-Closing-of-Final-Convertible-Debt-Issuance-for-Gross-Proceeds-of-US-5-0-Million.htmlNeovasc Announces Closing of Final Convertible Debt Issuance for Gross Proceeds of US$5.0 Million2020-06-04T13:00:00Z2020-06-07T10:12:17ZVANCOUVER and MINNEAPOLIS, MN, June 04, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, announced today that, further to its press release dated May 26, 2020, the Company has issued a final convertible note in the principal amount US$1 million to Strul Medical Group, LLC (“Strul”). Following the earlier issuance to Strul of a convertible note in the principal amount of US$4 million and 2,573,959 warrants (the “Warrants”), the Company has raised aggregate gross proceeds of US$5 million (the “Offering”). ]]>2043737enGlobeNewswire Inc.Neovasc, Inc.Thu, 04 Jun 2020 13:01 GMTFinancing AgreementsConvertible Debt IssuanceNVCNhttp://www.globenewswire.com/news-release/2020/06/04/2043629/0/en/Inovalon-s-2020-Annual-Meeting-of-Stockholders-Will-be-Virtual-Only.htmlInovalon’s 2020 Annual Meeting of Stockholders Will be Virtual Only2020-06-04T11:55:00Z2020-06-07T10:12:17ZBOWIE, Md., June 04, 2020 (GLOBE NEWSWIRE) -- Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, today announced that it will hold its 2020 annual meeting of stockholders in a virtual-only format due to health and safety concerns related to the ongoing COVID-19 pandemic and to comply with federal, state, and local restrictions on public gatherings. Stockholders will not be able to attend the annual meeting in person. The time and date of the annual meeting have not changed and the annual meeting will occur on Wednesday, June 17, 2020 at 10:00 a.m. Eastern Time, as previously announced. There is no change to the items of business to be addressed at the annual meeting, which are described in Inovalon’s proxy materials previously filed with the Securities and Exchange Commission.]]>2043629enGlobeNewswire Inc.Inovalon Holdings, Inc.Thu, 04 Jun 2020 11:55 GMTAnnual Meetings & Shareholder RightsCalendar of EventsHEALTHhealth analyticshealthcarehealthcare analyticshealthcare IThealthcare technologyCLOUD COMPUTINGhttp://www.globenewswire.com/news-release/2020/06/04/2043586/0/en/CareDx-to-Participate-at-the-Goldman-Sachs-Global-Healthcare-Conference.htmlCareDx to Participate at the Goldman Sachs Global Healthcare Conference2020-06-04T11:00:00Z2020-06-07T10:12:17ZSOUTH SAN FRANCISCO, Calif., June 04, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the company will be participating in the upcoming Goldman Sachs Global Healthcare Conference.]]>2043586enGlobeNewswire Inc.CareDx, Inc.Thu, 04 Jun 2020 11:00 GMTCalendar of Eventshttp://www.globenewswire.com/news-release/2020/06/03/2043106/0/en/BioSig-Technologies-Expands-Intellectual-Property-Portfolio.htmlBioSig Technologies Expands Intellectual Property Portfolio2020-06-03T15:45:00Z2020-06-07T10:12:17ZWestport, CT, June 03, 2020 (GLOBE NEWSWIRE) --

BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the U.S. Patent and Trademark Office (USPTO) has issued patent No. 10,645,017 titled “Systems, Apparatus and Methods for Conveying Biomedical Signals between a Patient and Monitoring and Treatment Devices,” which is intended to broadly protect the Company’s flagship product – the PURE EP(tm) System.

]]>2043106enGlobeNewswire Inc.BioSig Technologies, Inc.Wed, 03 Jun 2020 15:45 GMTCompany AnnouncementHEALTHMEDICALelectrophysiologystocknasdaqinvestorarrhythmiaAfibVTheartEPscienceablationbioelectronic medicineCOVID-19http://www.globenewswire.com/news-release/2020/06/03/2043091/0/fr/IBA-Information-r%C3%A9glement%C3%A9e.htmlIBA - Information réglementée2020-06-03T15:30:00Z2020-06-07T10:12:17ZLe 03 juin 2020, 17h30]]>2043091frGlobeNewswire Inc.IBA SAWed, 03 Jun 2020 15:30 GMTLaw & Legal IssuesEuropean Regulatory Newscorporatedenominatorhttp://www.globenewswire.com/news-release/2020/06/03/2043073/0/en/Medtronic-CEO-Geoff-Martha-to-Speak-at-Goldman-Sachs-Global-Healthcare-Conference.htmlMedtronic CEO Geoff Martha to Speak at Goldman Sachs Global Healthcare Conference2020-06-03T15:00:00Z2020-06-07T10:12:17ZDUBLIN, June 03, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it will participate in the Goldman Sachs 41st Annual Global Healthcare Conference, held virtually on Tuesday, June 9, 2020.]]>2043073enGlobeNewswire Inc.Medtronic plcWed, 03 Jun 2020 15:00 GMTCompany Announcementhttp://www.globenewswire.com/news-release/2020/06/03/2043027/0/en/Neovasc-Reducer-Spotlighted-in-Leading-German-Public-Television-Program.htmlNeovasc Reducer Spotlighted in Leading German Public Television Program2020-06-03T13:53:08Z2020-06-07T10:12:17ZElective Interventional Procedures Resume in Germany]]>2043027enGlobeNewswire Inc.Neovasc, Inc.Wed, 03 Jun 2020 13:52 GMTProduct / Services AnnouncementPress releasesNDR VisiteNVCNReducerhttp://www.globenewswire.com/news-release/2020/06/03/2042921/0/en/Sensus-Healthcare-and-David-Goldberg-M-D-J-D-to-Host-a-Virtual-Program-on-Dermatology-Medical-and-Legal-Issues-in-the-Era-of-COVID-19.htmlSensus Healthcare and David Goldberg, M.D., J.D. to Host a Virtual Program on Dermatology Medical and Legal Issues in the Era of COVID-192020-06-03T12:30:00Z2020-06-07T10:12:17ZJune 18 Event is the Third in a Series of Topical Discussions ]]>2042921enGlobeNewswire Inc.Sensus Healthcare, Inc.Wed, 03 Jun 2020 12:30 GMTPre-Release CommentsCompany Announcementhttp://www.globenewswire.com/news-release/2020/06/03/2042845/0/en/ESTA-Announces-Participation-in-the-Goldman-Sachs-Global-Healthcare-Conference.htmlESTA Announces Participation in the Goldman Sachs Global Healthcare Conference2020-06-03T12:00:00Z2020-06-07T10:12:17ZNEW YORK, June 03, 2020 (GLOBE NEWSWIRE) -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced that CEO and Founder Juan José Chacón-Quirós and Chief Financial Officer Renee Gaeta will participate in the Goldman Sachs 41st Annual Global Healthcare Conference Webcast, which is being held June 9-11, 2020. Mr. Chacón-Quirós and Ms. Gaeta are scheduled to speak to conference attendees at 3:00pm ET on Wednesday, June 10, 2020.]]>2042845enGlobeNewswire Inc.Establishment Labs Holdings IncWed, 03 Jun 2020 12:00 GMTCompany AnnouncementCalendar of Eventshttp://www.globenewswire.com/news-release/2020/06/02/2042600/0/en/Sarepta-Therapeutics-to-Present-at-Upcoming-Investor-Conferences.htmlSarepta Therapeutics to Present at Upcoming Investor Conferences2020-06-02T21:00:00Z2020-06-07T10:12:17ZCAMBRIDGE, Mass., June 02, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at two upcoming virtual investor conferences: ]]>2042600enGlobeNewswire Inc.Sarepta Therapeutics, Inc.Tue, 02 Jun 2020 21:00 GMTCalendar of Eventshttp://www.globenewswire.com/news-release/2020/06/02/2042267/0/en/Stereotaxis-Robotic-Technology-Now-Referenced-In-Over-400-Scientific-Publications.htmlStereotaxis Robotic Technology Now Referenced In Over 400 Scientific Publications2020-06-02T13:00:00Z2020-06-07T10:12:17ZST. LOUIS, June 02, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced it has reached a significant milestone of over 400 scientific publications now documenting the clinical benefits of Stereotaxis robotic technology. A complete, searchable database of all publications is available online at www.RoboticEP.com/Clinical-Data.]]>2042267enGlobeNewswire Inc.Stereotaxis, Inc.Tue, 02 Jun 2020 13:00 GMTCompany Announcementhttp://www.globenewswire.com/news-release/2020/06/02/2042276/0/en/Wisconsin-Health-System-Chooses-Cerner-s-Leading-Behavioral-Health-Technology.htmlWisconsin Health System Chooses Cerner’s Leading Behavioral Health Technology2020-06-02T13:00:00Z2020-06-07T10:12:17ZNorth Central Health Care Will Add Technology Across Three Multi-Specialty Facilities]]>2042276enGlobeNewswire Inc.Cerner CorporationTue, 02 Jun 2020 13:00 GMTHealthProduct / Services AnnouncementCernerNorth Central Health CareHealthcare IThealth IThttp://www.globenewswire.com/news-release/2020/06/02/2042221/0/en/Predictive-Oncology-Completes-Acquisition-of-Soluble-Therapeutics-and-BioDtech.htmlPredictive Oncology Completes Acquisition of Soluble Therapeutics and BioDtech2020-06-02T12:30:00Z2020-06-07T10:12:17ZMINNEAPOLIS, June 02, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (the “Company”) a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has completed the acquisition of the assets of Soluble Therapeutics, Inc. and BioDtech, Inc., each of which is a wholly-owned subsidiary of InventaBioTech, Inc. The Company acquired the assets of Soluble and BioDtech, including, certain intellectual property relating to contract research organization (“CRO”) services and technology, certain equipment useful in such services and technology and all other assets of Soluble Therapeutics and BioDtech for 125,000 shares of common stock, in addition to waiving all remaining amounts due and payable to the Company under a secured promissory note of InventaBioTech in the principal amount of $1,070,000 relating to advances made by the Company in 2017.]]>2042221enGlobeNewswire Inc.Predictive Oncology Inc.Tue, 02 Jun 2020 12:30 GMTMergers and Acquisitions